Premium
Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation
Author(s) -
Henninge John,
Pepaj Milaim,
Hullstein Ingunn,
Hemmersbach Peter
Publication year - 2010
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.233
Subject(s) - identification (biology) , growth hormone , peptide , human growth hormone , pharmacology , computational biology , medicine , hormone , chemistry , biology , biochemistry , botany
Several peptide drugs are being manufactured illicitly, and in some cases they are being made available to the public before entering or completing clinical trials. At the request of Norwegian police and customs authorities, unknown pharmaceutical preparations suspected to contain peptide drugs are regularly subjected to analysis. In 2009, an unknown pharmaceutical preparation was submitted for analysis by liquid chromatography‐high resolution tandem mass spectrometry (LC‐HRMS/MS). The preparation was found to contain a 29 amino acid peptide with a C‐terminal amide function. Based on the interpretation of mass spectrometric data, an amino acid sequence was proposed. The sequence is consistent with a peptide currently marketed under the name CJC‐1295. CJC‐1295 is a releasing factor for growth hormone and is therefore considered a Prohibited Substance under Section S2 of the WADA Prohibited List. This substance has potential performance‐enhancing effects, it is readily available, and there is reason to believe that it is being used within the bodybuilding community. Copyright © 2010 John Wiley & Sons, Ltd.